By Justin Leverenz, Chief Investment Officer, Developing Markets Equities China is unique among developing markets, not only ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...

Insilico Medicine said results of a clinical trial in China showed positive results in treating idiopathic pulmonary fibrosis ...

There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising ...

Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.

Now, many are returning to China, taking their skills, experience and professional contacts with them. The time is right for Western biotech and pharma companies to invest in and train a homegrown ...

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

While MIC2025 was officially shelved from public discourse in 2018 due to intense international backlash, its core objectives ...